Abiopharma

🔍 Shook David (Executive)

Company: Lyell Immunopharma, Inc. (LYEL)

Report Date: 2026-02-10

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-10 | Code: H | shares_owned_after: 21,900.00
• Acquired 50,000 shares of Option (right to buy) at $23.71 per share (Derivative)
  Date: 2026-02-10 | Code: A | Expires: 2036-02-09 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.